Successful treatment of an entecavir-resistant hepatitis B virus variant

Journal of Medical Virology

Volumn 79, Issue 12, 2007, Pages 1811-1817

  Yatsuji, Hiromi ^a,b,c   Hiraga, Nobuhiko ^a,b   Mori, Nami ^a,b   Hatakeyama, Tsuyoshi ^a,b   Tsuge, Masataka ^a,b   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Fujimoto, Yoshifumi ^b   Ochi, Hidenori ^b,d   Abe, Hiromi ^a,d   Maekawa, Toshiro ^d   Suzuki, Fumitaka ^c   Kumada, Hiromitsu ^c   Chayama, Kazuaki ^a,b,d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Adefovir; HBV; in vitro; Lamivudine; rtS202G

Indexed keywords

ADEFOVIR; ENTECAVIR; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; PHOSPHONIC ACIDS; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 35548950630     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20981     Document Type: Article

References (20)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Bruix J, Llovet JM. 2003. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 39:S59-S63.
3. Colonno RJ, Rose R, Baldick CJ, Leveine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. 2006. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656-1665.
4. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. 2003. The hepatitis B virus polymerase mutation rtV 173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833-11841.
5. Ganem D, Prince AM. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350:1118-1129.
6. Gunther S, Sommer G, Von Breunig F, Iwanska A, Kalinina T, Sterneck M, Will H. 1998. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: Frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol 36:531-538.
7. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
8. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36:687-696.
9. Lee YS, Suh DJ, Lim YS, Jung SW, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391.
10. Levine SD, Hernandez G, Yamanaka S, Zhang R, Rose R, Weinheimer S, Colonno RJ. 2002. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46:2525-2532.
11. Maecellin P, Asselah T. 2005. Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B. J Hepatol 43:920-923.
12. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
13. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449-455.
14. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313.
15. Sherman MC, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska, A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R. 2006. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130:2039-2049.
16. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30:743-748.
17. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48:3498-3507.
18. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. 2007. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51:902-911.
19. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46:531-538.
20. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok SF. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712.